Content Type: Article

  • FAQs on the Gender-Affirming Care Executive Order

    FAQs on the Gender-Affirming Care Executive Order

    FAQS / US POLICY

    FAQs on the Gender-Affirming Care Executive Order

    March 11, 2025

    Read time: 2 min

    Key takeaways
    Overview

    On January 28, 2025, the Trump administration issued an executive order that threatens federal research and education funding received by, and the Medicare and Medicaid participation of, medical institutions that provide gender-affirming care to individuals under the age of 19. Aspects of the executive order that jeopardize federal research and education funds have been enjoined nationally via several preliminary injunctions. However, regulatory and subregulatory actions on other aspects of the executive order are beginning to emerge. The executive order continues to present a myriad of legal and operational issues that medical institutions need to consider as they determine what actions, if any, to take in response to the executive order and the federal government’s efforts to implement it.

    This set of frequently asked questions (FAQs) provides an overview of these issues. It also discusses practical steps medical institutions should consider when evaluating their gender-affirming care programs in light of the executive order and federal efforts to restrict gender-affirming care for individuals under age 19 through the regulatory and subregulatory processes.

    In depth

    For information on the recent United States v. Skrmetti decision, download our related FAQs document which outline key takeaways for providers, hospitals, health systems, health plans, and employer plan sponsors who are navigating the implications of the ruling.

    Authors

    Travis Jackson

    Partner

    Los Angeles

    More insights

  • FAQs for Employers and Federal Contractors on Navigating the DEI Landscape

    FAQs for Employers and Federal Contractors on Navigating the DEI Landscape

    ARTICLE

    FAQs for Employers and Federal Contractors on Navigating the DEI Landscape

    February 14, 2025

    Read time: 2 min

    Key takeaways
    Overview

    On January 21, 2025, President Donald Trump issued several executive orders (EOs) eliminating diversity, equity, and inclusion (DEI) programs within the federal government. One of those orders, “Ending Illegal Discrimination and Restoring Merit-Based Opportunity,” outlines the significant policy change:

    It is the policy of the United States to protect the civil rights of all Americans and to promote individual initiative, excellence, and hard work. I therefore order all executive departments and agencies (agencies) to terminate all discriminatory and illegal preferences, mandates, policies, programs, activities, guidance, regulations, enforcement actions, consent orders, and requirements. I further order all agencies to enforce our longstanding civil-rights laws and to combat illegal private-sector DEI preferences, mandates, policies, programs, and activities. (emphasis added)

    President Trump’s EO requires every federal contractor to certify that “it does not operate any programs promoting DEI that violate any applicable Federal anti-discrimination laws.”

    This set of frequently asked questions is intended to help employers and federal contractors evaluate and navigate this EO.

    In depth
    Authors

    Tara L. Ward

    Partner

    Washington, DC

    More insights

  • SB 951 Revives Restrictive Oregon Law on Corporate Practice of Medicine

    SB 951 Revives Restrictive Oregon Law on Corporate Practice of Medicine

    ARTICLE / CLIENT ALERT

    SB 951 Revives Restrictive Oregon Law on Corporate Practice of Medicine

    February 14, 2025

    Read time: 8 min

    Key takeaways
    Overview

    On January 10, 2025, the Oregon Legislative Counsel introduced Senate Bill (SB) 951, aiming to modernize Oregon’s corporate practice of medicine (CPOM) doctrine. If enacted, SB 951would prohibit management services organizations (MSOs) and certain related parties from owning or controlling shares in, or otherwise controlling, the management operations of professional medical entities that may affect those entities’ clinical decision-making. SB 951 also would prohibit certain noncompetition and nondisclosure agreements. Such restrictions would become effective on January 1, 2026, for MSOs and professional medical entities incorporated or organized after the bill is enacted and on January 1, 2029, for entities in existence prior to the effective date of the bill.

    In depth

    Background

    On February 5, 2024, Representative Ben Bowman (D-OR) introduced House Bill (HB) 4130, which would implement sweeping CPOM restrictions on MSO ownership and management of professional medical entities. HB 4130 passed the Oregon House of Representatives with bipartisan support on February 22, 2024. However, the bill stalled at the state Senate president’s desk and failed to be enacted prior to the end of the legislative session. For a more detailed review of HB 4130, read our On the Subject, “Pending Oregon Law Undermines Traditional Physician Practice Structure.”

    Upon the adjournment of the 2024 legislative session, Rep. Bowman convened a “Workgroup on Oregon’s Corporate Practice of Medicine Doctrine” composed of stakeholders engaged with or otherwise interested in HB 4130. Over the course of the remainder of 2024, the working group discussed and proposed amendments to HB 4130’s provisions. In November 2024, the working group published a report on its findings and amendments to HB 4130, stating that the bill as amended would be introduced in the 2025 legislative session.

    SB 951 Changes to HB 4130

    Changes to the Control Provisions

    SB 951 would shift the liability for violations of the CPOM restrictions entirely to the MSO and away from the professional medical entity.

    HB 4130 would have prohibited professional medical entities from relinquishing control over their “assets, business operations, clinical practices or decisions or the clinical practices or decisions of a physician.” The limitations sought to ensure that the professional medical entity retains ultimate, or veto, control, even when contracting with an MSO, particularly with regard to clinical decision-making.

    SB 951 clarifies that the following MSO activities would not be prohibited:

    • Selling, leasing, or assigning the right to possess corporate assets, inclusive of any leased or owned property, to an MSO
    • Supporting, advising, and consulting on all matters of the professional medical entity’s business operations, including accounting and budgeting, personnel, real estate and facilities management, and compliance support, for the benefit of the professional medical entity
    • Advising and providing direction to the professional medical entity related to its participation in value-based contracts, payer arrangements, or vendor contracting.

    HB 4130 contained a carve-out for telemedicine, but SB 951 does not except as applicable to certain dual employment restrictions. Accordingly, practices providing telemedicine services without a physical presence in Oregon would be subject to the CPOM restrictions in SB 951.

    Changes to Dual Compensation (Ownership)

    HB 4130 contained a limitation on cross-ownership management whereby any shareholder, director, or officer of a professional medical entity would be prohibited from owning shares; being a director, officer, employee, or independent contractor; or participating in the management of a MSO under contract with the professional medical entity.

    SB 951 clarifies that MSOs owned by a professional medical entity and MSOs that are professional medical entities would not be subject to this prohibition by virtue of being owned and run by independent providers. Additionally, SB 951 includes an exception that would allow physicians and independent providers below the 10% ownership threshold to serve as directors or officers of the MSO, provided that such individuals are reimbursed at market rates for their services.

    Changes to Certain Key Contractual Clause Restrictions (Restrictive Covenants)

    HB 4130 proposed limitations to restrictive covenant clauses, including noncompetition, nondisclosure, and nondisparagement clauses, and limitations to stock transfer restriction agreements. HB 4130 would have voided any noncompetition agreements that prohibit Oregon licensed physicians from providing “products, processes or services.” HB 4130 also would have rendered unenforceable all nondisclosure and nondisparagement agreements between Oregon licensed physicians and MSOs.

    SB 951 clarifies that noncompetition agreements with providers who have ownership would be allowed, although such agreements with providers with zero or less than 10% ownership stake in the professional medical entity would remain void and unenforceable. Noncompetition agreements for providers not directly engaged in clinical care also would be allowed, although such agreements would be rendered unenforceable should the provider’s employment to provide clinical care terminate.

    Under SB 951, nondisclosure and nondisparagement agreements remain void and unenforceable, except as it relates to trade secrets, good-faith reports, and in termination agreements with whistleblower protections.

    SB 951, similarly to HB 4130, would prohibit stock transfer restriction agreements broadly but provides a limited list of exceptional circumstances under which a stock transfer restriction agreement would be permitted:

    • Suspension or revocation of a shareholder’s or member’s professional license in Oregon or another state
    • A shareholder’s or member’s disqualification from holding stock or interest in the professional medical entity
    • A shareholder’s or member’s exclusion, debarment, or suspension from a federal healthcare program or an investigation that could result in the shareholder’s or member’s exclusion, debarment, or suspension
    • A shareholder’s or member’s indictment for a felony or another crime that involves fraud or moral turpitude
    • Dissolution of the professional medical entity
    • Termination or breach of a contract for management services between a shareholder and an MSO or the professional medical entity.

    Enforcement

    HB 4130 would have empowered the secretary of state to investigate any complaint from the Oregon Health Authority (OHA) or any other person about a violation of these restrictions and to administratively dissolve or revoke the foreign qualification of offending organizations.

    SB 951 removes the secretary of state’s involvement; instead, it would regulate violations under the Unlawful Trade Practices Act and authorize OHA to stop pending or future transactions that violate the statute.

    Key Definitions

    • “Management services” means services for or on behalf of a professional medical entity that include payroll, human resources, employment screening, employee relations, or any other administrative or business services that support or enable a professional medical entity’s medical purpose and do not include practicing medicine; enabling joint rendering of professional health services by physicians, physician assistants, and nurse practitioners; or practicing naturopathic medicine.
    • “Management services organization” means an entity that under a written agreement and in return for compensation provides management services to a professional medical entity but does not include a hospital or a hospital-affiliated clinic.
    • “Medical purpose” means the purpose of practicing medicine; the purpose of allowing physicians, physician assistants, and nurse practitioners to jointly render professional healthcare services; or the purpose of practicing naturopathic medicine.
    • “Professional medical entity” includes a professional corporation; a limited liability company or foreign limited liability company with authority to transact business in Oregon that is organized for a medical purpose; a partnership or limited liability partnership, or foreign partnership or foreign limited liability partnership with authority to transact business in Oregon, that is organized for a medical purpose; or a limited partnership or foreign limited partnership with authority to transact business in Oregon that is organized for a medical purpose.

    Analysis

    SB 951 continues the nationwide trend toward increased regulation of healthcare transactions and represents a small step back from the onerous restrictions and prohibitions presented in its predecessor, HB 4130. SB 951 still contains much of the same restrictions while providing incremental concessions to certain MSO practices.

    If passed, SB 951 would significantly impair current and future transaction structures that utilize MSOs in Oregon. Considering its predecessor stalled in the Senate, SB 951 is likely to face similar challenges.

    McDermott will continue to monitor the bill’s progression through the state legislature and provide updates.

    Key Takeaways

    If SB 951 is passed:

    • Professional medical entities would be prohibited from relinquishing control over their “assets, business operations, clinical practices or decisions or the clinical practices or decisions of a physicians,” greatly restricting the current MSO framework in Oregon.
    • Shareholders, directors, and officers of professional medical entities would be prohibited from owning shares of; being a director, officer, employee, or independent contractor of; or participating in the management of an MSO under contract with the professional medical entity, except under limited circumstances.
    • Restrictive covenant agreements would be largely rendered void and unenforceable with regard to professional medical entities and MSOs.
    • Stock transfer restriction agreements between professional medical entities and MSOs would be significantly limited to certain enumerated circumstances.
    Authors

    Larry C. Guess

    Partner

    Chicago

    Patrick Zanayed

    Partner

    Chicago

    Jae Hyun Lee

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • President Trump Issues Executive Order Targeting DEI Programs, and Ensuing Legal Developments

    President Trump Issues Executive Order Targeting DEI Programs, and Ensuing Legal Developments

    ARTICLE / CLIENT ALERT

    President Trump Issues Executive Order Targeting DEI Programs, and Ensuing Legal Developments

    February 14, 2025

    Read time: 8 min

    Key takeaways
    Overview

    On Jan. 21, 2025, President Trump issued Executive Order 14173 (“Order”), entitled “Ending Illegal Discrimination And Restoring Merit-Based Opportunity.” This Order will have significant impact on Diversity, Equity and Inclusion (“DEI”) policies, practices and programs implemented by private sector employers as well as within the federal government. Subsequent legal developments concerning the Order may impact the practical effect of the Order.

    Specifically, the Order instructs all executive departments and federal agencies to “terminate all discriminatory and illegal preferences, mandates, policies, programs, activities, guidance, regulations, enforcement actions, consent orders, and requirements” and further orders all federal agencies “to combat illegal private-sector DEI preferences, mandates, policies, programs, and activities.” Under Section 3 of the Order, several prior executive orders are revoked, including Executive Order 11246 (1965) — the longstanding order that prohibited discrimination and required the development of affirmative action plans to ensure equal opportunity in federal contracting. The Order directs the Office of Federal Contract Compliance Programs (“OFCCP”) within the Department of Labor to immediately cease (i) promoting diversity, enforcing affirmative action initiatives, and (ii) allowing or encouraging federal contractors and subcontractors to engage in workforce balancing based on protected characteristics. Additionally, the Order instructs agencies to include in all federal contracts or grant awards a provision requiring federal contractors to certify that they do not operate any programs promoting DEI “that violate any applicable Federal anti-discrimination laws.” Federal contractors may continue to comply with Executive Order 11246 and its existing regulatory framework for 90 days from Jan. 20, 2025. The impact of the Order on pending compliance reviews, complaint investigations or other enforcement activities by the OFCCP is unknown; however, federal contractors should expect to see language implementing this directive in new procurements and modifications to existing contracts.

    Section 4 of the Order focuses on DEI programs in the private sector by directing the Attorney General of the United States to submit a report, within 120 days of the Order (i.e., on or about May 21, 2025), with “recommendations for enforcing Federal civil-rights laws and taking other appropriate measures to encourage the private sector to end illegal discrimination and preferences, including DEI.” The Attorney General’s report must contain a “strategic enforcement plan” identifying:

    • Key sectors of concern within each agency’s jurisdiction;
    • Private sector companies with the most “egregious and discriminatory” DEI programs;
    • A plan to deter DEI programs “that constitute illegal discrimination or preferences.” As part of the plan, agencies are directed to identify up to 9 potential investigations of publicly traded corporations, large non-profit corporations or associations, foundations with assets over $500M, state and local bar and medical associations, and universities with endowments over $1B;
    • Litigation that would be potentially appropriate for Federal lawsuits, intervention or statements of interest; and
    • Potential regulatory action and sub-regulatory guidance.

     

    Legal Action Following the Issuance of President Trump’s Executive Order

    On Feb. 3, 2025, a group of plaintiffs, including university diversity officers, college professors, restaurant workers, the City of Baltimore, and Baltimore City Council, filed a complaint in federal court in Maryland challenging the constitutionality of the Order, as well as challenging Executive Order 14151, entitled “Ending Radical and Wasteful Government DEI Programs and Preferencing.”

    The lawsuit, filed in the US District Court for the District of Maryland, alleges that these executive orders are unconstitutional on multiple grounds. The complaint alleges that Sections 3 and 4 of the Order, which impact federal contractors and the private sector, violate the Free Speech Clause of the First Amendment because the “threat of ‘civil compliance investigations’ impermissibly restricts the exercise of [plaintiffs] constitutionally protected speech based on its content and viewpoint.”

    Additionally, the plaintiffs claim that the Order is unconstitutionally vague in violation of the Due Process Clause of the Fifth Amendment. According to the complaint, the Order fails to provide an ordinary person with fair notice of the prohibited conduct and fails to define material terms, including “DEI,” “illegal DEI,” and “equity-related” that determine whether an entity will be subject to civil investigation or enforcement. The lawsuit seeks preliminary and permanent injunctive relief to enjoin the enforcement of the executive orders.

    State Attorney General Actions in Response to the Order

    Two days after the issuance of the Order, Texas Attorney General Ken Paxton, joined by nine other Attorneys General (from AL, ID, IN, IA, MT, NE, SC, UT and VA) sent a letter to six major financial institutions challenging their DEI and environmental, social and governance (“ESG”) programs. The letter included requests for information and directed specific questions to the financial institutions regarding their DEI and ESG programs as an “opportunity to avoid a lengthy enforcement action.” The letter further threatened potential legal action against these institutions for alleged violations of federal and/or state law.

    Previously, on Jan. 31, 2025, New York Attorney General Letitia James and eleven other state Attorneys General (from CA, CT, DE, IL, HA, MA, MD, MN, NJ, VT and WA) issued a joint statement addressing and opposing President Trump’s recent executive orders pertaining to DEI policies and programs.

    The statement criticized the executive orders as “unnecessary and disingenuous,” arguing that the executive orders ineffectively combat discriminatory practices. According to the January 31st statement: “President Trump’s attack on diversity, equity, inclusion, and accessibility initiatives undermines a simple and unassailable goal: to create fairer workplaces and opportunities for all to succeed.” Further, the statement argues that DEI initiatives help prevent discrimination while promoting respect and understanding of diverse perspectives to ensure fair treatment and equal access to opportunities.

    US Attorney General’s Memorandum on DEI

    On Feb. 5, 2025, Attorney General Pam Bondi issued a memorandum, entitled “Ending Illegal DEI and DEIA Discrimination and Preferences,” which directs the Department of Justice’s Civil Rights Division (“DOJ Civil Rights Division”) to investigate “illegal DEI and DEIA preferences, mandates, policies, programs, and activities in the private sector and in educational institutions that receive federal funds.” The memorandum directs the DOJ Civil Rights Division and Office of Legal Policy to jointly submit a report to the Associate Attorney General by March 1, 2025, containing recommendations for enforcing federal civil rights laws and “taking other appropriate measures to encourage the private sector to end illegal discrimination and preferences.” Consistent with the requirements of the Order, the report must, among other things, identify specific measures to deter the use of DEI programs that constitute illegal discrimination, “including proposals for criminal investigations and for up to nine potential civil compliance investigations of entities that meet the criteria outlined” in the Order. These entities include publicly traded corporations, large non-profit corporations or associations, foundations with assets of $500 million or more, state and local bar and medical associations, and institutions of higher education with endowments over $1 billion.

    Notably, the memorandum explicitly states in a footnote that cultural heritage month celebrations and historical observances that promote diversity and awareness without engaging in discriminatory exclusion are not being targeted. Further, the memorandum also previews guidance to the Department of Education on how educational agencies, colleges, and universities are expected to respond to the Order, noting that the DOJ Civil Rights Division will pursue actions against these entities as well.

    Implications and Next Steps

    In light of these recent developments, including the threat of potential governmental investigations and litigation, employers should evaluate their current DEI-related policies, practices and programs by conducting legally-privileged audits and risk assessments, including to ensure compliance with existing anti-discrimination statutes such as Title VII. Any DEI initiative which uses race, gender or similar classification as an eligibility criterion should be particularly analyzed, including those policies, practices and programs related to recruitment, hiring, workplace affinity and culture, and promotion. DEI-related policies and programs that broaden the applicant pool for recruitment purposes, while not establishing a quota, mandate or use race or gender as an eligibility requirement, should still be acceptable. Care should be taken as well with respect to language used in describing DEI initiatives on websites and other public disclosures. We will continue to monitor developments in this area, and expect further guidance upon the issuance of the Attorney General’s report.

     

    Authored by Mark E. Brossman, Ronald E. Richman, Martin L. Schmelkin, Max Garfield and Danisa Foote.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    Martin L. Schmelkin

    Partner

    New York – 919 Third Avenue

    Max Garfield

    Partner

    New York – 919 Third Avenue

    More insights

  • ECJ on the future of (data protection) company agreements: What will change?

    ECJ on the future of (data protection) company agreements: What will change?

    ARTICLE

    ECJ on the future of (data protection) company agreements: What will change?

    February 13, 2025

    Read time: 2 min

    Key takeaways
    Overview

    The HR News blog provides regular updates on recent developments in German employment law (in German).

    In the latest HR NEWS article (German), Dr. Philip Uecker provides an overview of whether and how companies need to adapt their works agreements.

    Visit the blog and/or register now for regular HR NEWS updates (in German).

    In depth
    Authors

    Dr. Philip Uecker

    Associate

    Düsseldorf

    More insights

  • CLOs and Material Nonpublic Information: Key Takeaways from the SEC’s Settlement with Sound Point

    CLOs and Material Nonpublic Information: Key Takeaways from the SEC’s Settlement with Sound Point

    ARTICLE

    CLOs and Material Nonpublic Information: Key Takeaways from the SEC’s Settlement with Sound Point

    13. Februar 2025

    Read time: 2 min

    Key takeaways
    Overview

    In this alert, we present the key lessons to be learned from the U.S. Securities and Exchange Commission’s (the SEC) settlement with Sound Point Capital Management, LP (Sound Point), and discuss whether a similar enforcement action would be possible under the EU and UK market abuse regimes.

    Read the full article written by Vlad Maly, Paul Helms and Michal Chajdukowski on our FinRegNews Blog.

    Sign up now for regular FinRegNews updates.

    In depth
    Authors

    Vlad Maly

    Partner

    London – 22 Bishopsgate

    Paul M.G. Helms

    Partner

    Chicago, Washington, DC

    More insights

  • New Schedule 13D/G C&DIs Published by SEC Staff Regarding Shareholder Engagement and Active/Passive Status

    New Schedule 13D/G C&DIs Published by SEC Staff Regarding Shareholder Engagement and Active/Passive Status

    ARTICLE / CLIENT ALERT

    New Schedule 13D/G C&DIs Published by SEC Staff Regarding Shareholder Engagement and Active/Passive Status

    February 13, 2025

    Read time: 7 min

    Key takeaways
    Overview

    On Feb. 11, 2025, the staff of the Division of Corporation Finance at the Securities and Exchange Commission published revisions to existing Securities and Exchange Act Sections 13(d) and 13(g) and Regulation 13D-G Compliance and Disclosure Interpretation (C&DI) Question 103.11 and published new Question 103.12 regarding how engagement with issuers may affect a beneficial owner’s active/passive status.[1] 

    While the new C&DI maintains that facts and circumstances are critical in determining a shareholder’s eligibility to report on Schedule 13G, investors should carefully consider this new Staff guidance. The new C&DI appears aimed at asset managers that share social, environmental, political or governance related policies with an issuer and couple their expressions of policy with explicit or implicit statements related to withholding support from the issuer’s board candidates. It is notable that the C&DI changes are consistent with acting Chairman Mark T. Uyeda’s Remarks at the 2022 Cato Summit on Financial Regulation.[2]

    As always, engagement teams should carefully consider how they integrate expressions of policy and voting intentions/decisions into discussions with any issuer.

    See below for the full text of the changes to C&DI 103.11 and new C&DI 103.12.

    Question 103.11

    • Question: The Hart-Scott-Rodino (“HSR”) Act provides an exemption from the HSR Act’s notification and waiting period provisions if, among other things, the acquisition of securities was made “solely for the purpose of investment,” with the acquiror having “no intention of participating in the formulation, determination, or direction of the basic business decisions of the issuer.” 15 U.S.C. 18a(c)(9); 16 C.F.R. 801.1(i)(1). Does the fact that a shareholder is disqualified from relying on this HSR Act exemption due to its efforts to influence management of the issuer on a particular topic, by itself, disqualify the shareholder from initially reporting, or continuing to report, beneficial ownership on Schedule 13G?
    • Answer: The inability to rely on the HSR Act exemption alone would not preclude a shareholder from filing on Schedule 13G in lieu of the Schedule 13D otherwise required. Instead, eligibility to usereport on Schedule 13G under Exchange Actin reliance on Rule 13d-1(b) or Rule 13d-1(c) will depend, among other things, on whether the shareholder acquired or is holdingequitythe subject securities with the purpose or effect of changing or influencing control of the issuer. This determination is based upon all the relevant facts and circumstances. and will be informed by the meaning of “control” as defined in Exchange Act Rule 12b-2. [Feb. 11, 2025]
    • The subject matter of the shareholder’s discussions with the issuer’s management may be dispositive in making this determination, although the context in which the discussions occur is also highly relevant. For example:
    • Generally, engagement with an issuer’s management on executive compensation and social or public interest issues (such as environmental policies), without more, would not preclude a shareholder from filing on Schedule 13G so long as such engagement is not undertaken with the purpose or effect of changing or influencing control of the issuer and the shareholder is otherwise eligible to file on Schedule 13G. See Release No. 34-39538 (Jan. 12, 1998)(stating that a shareholder’s proposal or soliciting activity relating to such topics generally would not cause a loss of Schedule 13G eligibility).
    • Engagement on corporate governance topics, such as removal of staggered boards, majority voting standards in director elections, and elimination of poison pill plans, without more, generally would not disqualify an otherwise eligible shareholder from filing on Schedule 13G if the discussion is being undertaken by the shareholder as part of a broad effort to promote its view of good corporate governance practices for all of its portfolio companies, rather than to facilitate a specific change in control in a particular
    • By contrast, Schedule 13G would be unavailable if a shareholder engages with theissuer’s management on matters that specifically call for the sale of the issuer to another company, the sale of a significant amount of the issuer’s assets, the restructuring of the issuer, or a contested election of directors. [July 14, 2016]

    Question 103.12

    • Question: Shareholders filing a Schedule 13G in reliance on Rule 13d-1(b) or Rule 13d-1(c) must certify that the subject securities were not acquired and are not held “for the purpose of or with the effect of changing or influencing the control of the issuer.” Under what circumstances would a shareholder’s engagement with an issuer’s management on a particular topic cause the shareholder to hold the subject securities with a disqualifying “purpose or effect of changing or influencing control of the issuer” and, pursuant to Rule 13d-1(e), lose its eligibility to report on Schedule 13G?
    • Answer: The determination of whether a shareholder acquired or is holding the subject securities with a purpose or effect of “changing or influencing” control of the issuer is based on all the relevant facts and circumstances and will be informed by the meaning of “control” as defined in Exchange Act Rule 12b-2.

    The subject matter of the shareholder’s engagement with the issuer’s management may be dispositive in making this determination. For example, Schedule 13G would be unavailable if a shareholder engages with the issuer’s management to specifically call for the sale of the issuer or a significant amount of the issuer’s assets, the restructuring of the issuer, or the election of director nominees other than the issuer’s nominees.

    In addition to the subject matter of the engagement, the context in which the engagement occurs is also highly relevant in determining whether the shareholder is holding the subject securities with a disqualifying purpose or effect of “influencing” control of the issuer. Generally, a shareholder who discusses with management its views on a particular topic and how its views may inform its voting decisions, without more, would not be disqualified from reporting on a Schedule 13G. A shareholder who goes beyond such a discussion, however, and exerts pressure on management to implement specific measures or changes to a policy may be “influencing” control over the issuer. For example, Schedule 13G may be unavailable to a shareholder who:

    • recommends that the issuer remove its staggered board, switch to a majority voting standard in uncontested director elections, eliminate its poison pill plan, change its executive compensation practices or undertake specific actions on a social, environmental or political policy and, as a means of pressuring the issuer to adopt the recommendation, explicitly or implicitly conditions its support of one or more of the issuer’s director nominees at the next director election on the issuer’s adoption of its recommendation; or
    • discusses with management its voting policy on a particular topic and how the issuer fails to meet the shareholder’s expectations on such topic, and, to apply pressure on management, states or implies during any such discussions that it will not support one or more of the issuer’s director nominees at the next director election unless management makes changes to align with the shareholder’s expectations. [Feb. 11, 2025]

    Authored by Ele Klein, Adriana Schwartz, Sean Brownridge and Brandon Gold.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] SEC.gov | Exchange Act Sections 13(d) and 13(g) and Regulation 13D-G Beneficial Ownership Reporting.

    [2] SEC.gov | Remarks at the 2022 Cato Summit on Financial Regulation


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Ele Klein

    Partner

    New York – 919 Third Avenue

    Brandon S. Gold

    Partner

    New York – 919 Third Avenue

    More insights

  • New HSR Rules Go Live: Your Playbook for Effective M&A

    New HSR Rules Go Live: Your Playbook for Effective M&A

    ARTICLE / CLIENT ALERT

    New HSR Rules Go Live: Your Playbook for Effective M&A

    February 10, 2025

    Read time: 7 min

    Key takeaways
    Overview

    Starting today, February 10, 2025, all merger filings will be subject to new Hart-Scott-Rodino (HSR) rules. The new HSR rules will fundamentally alter the premerger notification process, and substantially increase the burden on filing parties, who will need to provide significantly more information and documents with their initial filings.

    Companies can take steps today to make filings under the new rules less burdensome and increase the likelihood of achieving antitrust clearance, such as collecting and regularly updating the “off-the-shelf” information needed for all filings, and engaging in earlier discussions with the legal team to identify potential overlaps and supply relationships and develop key themes around transaction rationales and impacts on competition that will need to be included in the filing.

    In depth

    Major Changes

    The two biggest changes in the new HSR rules are the requirements to (1) submit new business descriptions of transaction rationales, competitive overlaps, and supply relationships; and (2) submit more business documents with the filing, including ordinary course strategic documents presented to the CEO or board of directors.

    New Business Descriptions

    • For all transactions, the merging parties must:
      • Describe each of the principal categories of their products and services.
      • Identify and explain each strategic rationale for the transaction discussed or contemplated (including rationales later abandoned).
    • For transactions with competitive overlaps, the merging parties must:
      • Identify and describe the current products or services that compete with, or could compete with, the other party – including known planned products or services in development.
      • Submit data on sales of such products in the most recent year, a description of all categories of customer types by product (e.g., retailer, distributor, commercial, residential), and the top 10 customers for the product, and each customer category identified.
    • For transactions in which the parties have supply relationships, the merging parties must:
      • Describe each product or service (1) supplied to the other party or another entity that competes with that party, or (2) purchased or otherwise obtained from the other party or another entity that competes with that party; in both cases, above a de minimis threshold.
      • Submit data on sales or purchases from the other party and/or another entity that competes with that party, and the top 10 customers or suppliers for each such product or service.

    More Business Documents

    • For all transactions, merging parties must include:
      • Transaction-related documents.
        • Parties must provide materials equivalent to what were formerly referred to as “Item 4 documents” and include confidential information memoranda, and documents that discuss the transaction in terms of markets, market shares, competitors, competition, synergies/efficiencies, and opportunities for sales growth/expansion into markets.
        • There is a new requirement to collect such documents not only from officers and directors, but also from the “Supervisory Deal Team Lead,” defined as the individual with the primary responsibility for supervising the strategic assessment of the transaction.
        • Draft documents presented to any board member must be included, unless the board member received such drafts in a deal team role and not in a capacity as a board member (clarified in recent “two hats” guidance from the Federal Trade Commission).
    • For transactions with competitive overlaps, merging parties must also include:
      • Ordinary course Plans and Reports (from within one year of filing), even if not prepared in connection with the transaction.
        • All documents shared with the board that discuss markets, market shares, competitors, or competition for the overlap product or service.
        • All regularly prepared reports (annual, semi-annual, or quarterly) shared with the CEO that discuss markets, market shares, competitors, or competition for the overlap product or service.

    Other Key Changes

    CATEGORY NEW OR UPDATED REQUIREMENTS
    Officers and Directors New requirement to identify officer or director interlocks with other businesses that have a vertical or horizontal competitive relationship with the target business.
    Minority Shareholders or Interest Holders Requires identifying minority holders (more than 5%, but less than 50%) anywhere in the acquiring entity’s corporate chain.
    Limited partners need to be identified if they have the right to influence the Board, such as by having the right to appoint or nominate a member – previously only general partners of limited partnerships needed to be listed.
    NAICS Codes Require filing persons to identify which operating business contributes to each North American Industry Classification System (NAICS) code.
    Prior Acquisitions Both buyer and target need to report certain prior acquisitions involving products or services in the Overlap Description (not just NAICS overlap).
    Defense/Intelligence Community Contracts Must report contracts valued at $100 million or more involving horizontal overlaps or vertical supply relationships.
    Foreign Subsidies Must report financial subsidies from certain foreign countries or entities (e.g., China, Russia, Iran, North Korea).

    Implications for Merging Parties

    Earlier Antitrust Counsel Involvement is Critical

    • Assessing Overlaps
      • The data and documents needed to file differs significantly for transactions with competitive overlaps, therefore determining whether there is an overlap early in the process can significant benefit this workstream – overlap deals may require bringing more employees “in the tent” to facilitate gathering of necessary documents, data, and information.
      • Exchanging NAICS codes with other party (via antitrust counsel) should be advanced earlier in the process. Sellers should consider pushing buyers for overlap input earlier in the process because filings with even limited overlaps (and no significant antitrust issues) under the new HSR rules will, nonetheless, require substantially more preparation to file.
      • Reviewing ordinary course strategic documents that will be filed is critical, because overlap descriptions in the filing need to be consistent with such documents.
    • Developing – and Documenting – Key Themes
      • More documents being submitted with the initial filing provides more opportunities for government agencies to identify and investigate potential issues.
      • It is important that these documents are accurate and based on real data/facts and avoid content that can be misconstrued in a way that could be harmful for competition reviews. Employees at portfolio companies who prepare such documents presented to the company CEO or the board should consult and share drafts with the legal team before sharing/finalizing.
      • Early discussions with the legal team to develop and document transaction rationales is important because parties must in their business descriptions, explain any inconsistencies with Business Documents.

    Changes to Antitrust Provisions in Purchase Agreements

    • Timing 
      • The time to prepare an HSR filing is substantially increased under the new HSR rules.
      • HSR timing provisions will need to be updated to provide greater time/flexibility (e.g., no longer a specific timeline, but a shift to “as soon as reasonably practicable”; longer timelines, such as 20 business days or 30 days).
      • Pre-signing HSR preparation is critical to be able to proceed quickly.
    • Cooperation
      • With more advocacy and documents submitted with the initial filing, more robust cooperation provisions should be incorporated into purchase agreements to cover sharing of the draft filings/submissions between counsel.

    Steps That Clients Can Take Now to Maker HSR Filings More Efficient and Successful

    Companies can consider the following steps to prepare for the new filing regime:

    1. With counsel, draft high-level descriptions for each active portfolio company investment or operating company, describing each of the products and/or services provided by the company.
    2. Maintain a list of NAICS codes for each active operating business.
    3. Develop a list of minority shareholders holding more than 5% but less than 50% of each holding company, fund, portfolio company, and/or subsidiaries.
    4. Create a list of prior acquisitions within the previous five years for each portfolio company, organized by product or service lines.
    5. Collect and organize all board documents and regularly prepared documents shared with the CEO that discuss markets, market shares, competitors, or competition.
    6. Refresh – and expand – document creation training for employees likely to draft Business Documents.

    For additional details on the new HSR rules and their implications for M&A strategy, see our client alert and webinar recording from October 2024. To discuss how best to implement the new rules on your next HSR filing, contact your regular McDermott lawyer or the authors of this article.

    Authors

    Gregory E. Heltzer

    Partner

    Washington, DC

    Noah Feldman Greene

    Partner

    Washington, DC

    Jon B. Dubrow

    Partner

    Washington, DC

    More insights

  • Exchange Act Rule 13f-2 and Related Form SHO Update: SEC Provides a One-Year Exemption From Rule 13f-2 Compliance

    Exchange Act Rule 13f-2 and Related Form SHO Update: SEC Provides a One-Year Exemption From Rule 13f-2 Compliance

    ARTICLE / CLIENT ALERT

    Exchange Act Rule 13f-2 and Related Form SHO Update: SEC Provides a One-Year Exemption From Rule 13f-2 Compliance

    February 8, 2025

    Read time: 4 min

    Key takeaways
    Overview

    On Feb. 7, 2025, the US Securities and Exchange Commission (the “SEC”) announced a one-year temporary exemption from compliance with Exchange Act rule 13f-2 (“Rule 13f-2”) and accompanying Form SHO filing requirements (the “Exemptive Relief”).[1] This temporary relief makes January 2026 the first Rule 13f-2 reporting period, with the first Form SHO filings due by Feb. 17, 2026.[2]

    Rule 13f-2 became effective Jan. 2, 2024, and requires that institutional investment managers that exercise investment discretion over gross short positions in equity securities exceeding certain reporting thresholds submit a Form SHO filing to the SEC within fourteen (14) calendar days of month end.[3] Prior to the exemptive relief, January 2025 was set to be the first Rule 13f-2 reporting period, with Form SHO filings due by Feb. 14, 2025.[4]

    The Exemptive Relief is welcome news to industry participants, who have cited a number of concerns relating to Rule 13f-2, including interpretative issues relating to the rule’s reporting requirements and the quick turnaround between the end of the reporting period and the filing deadline. SEC Acting Chairman Uyeda noted that this temporary relief “gives filers more time to implement the technical updates required for compliance,”[5] while affirming that the SEC will continue to monitor and combat illegal short selling activity.[6]

    The industry is hoping the SEC will issue additional guidance regarding Form SHO during the exemption period. Industry members should notify the SEC of areas of confusion or concern if they have not done so already.

    There remains ongoing litigation by industry groups aiming to vacate Rule 13f-2 and Exchange Act rule 10c-1a (which requires reporting of covered securities loans to FINRA on a daily basis).[7] We anticipate a decision in the litigation in the coming months and will continue to monitor for developments related to Rule 13f-2 and Form SHO.

    Authored by William Barbera, Marc Elovitz, Kelly Koscuiszka, Adriana Schwartz and Derek Lacarrubba.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] See Exchange Act Release No. 34-102380 (Feb. 7, 2025) (the “Exemptive Order”). See also SEC Press Release, Exemption From Exchange Act Rule 13f-2 and Related Form SHO (the “SEC Press Release”).

    [2] See Exemptive Order at p. 6.

    [3] For more information on Exchange Act Rule 13f-2 and Form SHO, please see our prior Alerts: “SEC Adopts Short Reporting Rule for Institutional Investment Managers with Global Scope” and “Reminder: SEC Short Position (Form SHO) Filing Deadline Fast Approaching.”

    [4] Id.

    [5] See SEC Press Release.

    [6] Id.

    [7] Nat’l Assoc. Priv. Fund Mgr. v. SEC, No. 23-60626 (5th Cir.). This lawsuit is ongoing as of the date of this publication. Review the petition.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    William J. Barbera

    Partner

    New York – 919 Third Avenue

    Marc E. Elovitz

    Partner

    New York – 919 Third Avenue

    Kelly Koscuiszka

    Partner

    New York – 919 Third Avenue

    More insights

  • Trump, Court Actions Curtail Union Involvement in Federal Contracts

    Trump, Court Actions Curtail Union Involvement in Federal Contracts

    CLIENT ALERT / US POLICY

    Trump, Court Actions Curtail Union Involvement in Federal Contracts

    February 7, 2025

    Read time: 5 min

    Key takeaways
    Overview

    Federal contractors spent the past three years navigating executive mandates limiting their ability to select their own workforces after being awarded a large federal service contract. These mandates also required them to use unionized workforces on certain federal construction projects, even when these requirements increased costs or delayed project completion. In the span of two days, the Trump administration and the US Court of Federal Claims took successive action to remove some of these requirements, providing federal contractors greater flexibility in managing their workforces and costs when bidding on and fulfilling federal contracts:

    • On January 20, 2025, President Donald Trump revoked a Biden administration rule requiring federal contractors to offer continued employment to their predecessor’s employees, even when the predecessor’s unionized employees may not be ideally suited to fulfill the contract at issue. The Biden executive order (EO) made successor contractors “perfectly clear successors” under the National Labor Relations Act (NLRA) when the predecessor contractor had a unionized workforce. The “perfectly clear successor” designation required the successor contractor to bargain initial terms with the union or recognize an existing collective bargaining agreement.
    • On January 21, 2025, the US Court of Federal Claims invalidated a Biden administration mandate that all federal contractors awarded construction projects costing $35 million or more use unionized workers, in large part because the government’s own studies established that the mandate was anticompetitive and increased costs.

    The net result of these actions is that contractors can once again bid for and execute federal contracts to the best of their ability and in a cost-effective manner without having to assume certain obligations to union employees. Federal contractors should review current and upcoming bidding opportunities to determine if they can offer increased savings over incumbents through more competitive pricing.

    In depth

    Elimination of Employees’ “Right of First Refusal”

    Before January 2025, any federal contractor that won a service contract valued at more than $250,000 was required to offer existing employees a “right of first refusal” before hiring a new workforce. For example, a contractor that won a facility maintenance contract previously held by a different contractor must offer the prior contractor’s employees’ jobs before hiring its own candidates. This often led to legal obligations and operational issues, including the following:

    • Under the NLRA, a successor employer acquiring a unionized operation may set its own initial terms of employment for union employees prior to bargaining, unless the successor employer is a “perfectly clear successor.” A successor is a “perfectly clear successor” if it intends to hire all, or virtually all, the predecessor’s employees. A “perfectly clear successor” cannot set its own initial employment terms before bargaining with the union and must comply with all its predecessor’s obligations, including any existing collective bargaining agreements and/or bargaining obligations. As a result, the Biden EO’s “right of first refusal” often acted as a requirement that contractors interested in bidding on certain service agreements be willing to assume union bargaining obligations as the cost of entry, even when doing so impacted their ability to perform the contract on budget.
    • The predecessor may have been saddled with staffing or employment contracts objectively shown to increase costs and delay fulfillment of the contract’s requirements.

    No more. Now, federal contractors must focus on cost-effectiveness and efficiency when determining how to staff new contracts, even when that means hiring new employees.

    Elimination of Mandatory Project Labor Agreements

    Project labor agreements (PLAs) are collective bargaining agreements between a contractor and a union covering workers on a specific construction project. Until January 2025, an EO issued by former President Joe Biden required any federal contractor capable of bidding on a large construction project valued over $35 million to execute a PLA with a union just to be eligible for the contract.

    The impact of this order was stark: When a contractor without a PLA submitted a competitive bid that was under budget, it was rejected out of hand, even if every other bidder came in over budget based on costs associated with their PLAs. Consequently, these contractors were forced to recognize and bargain with a union if they were awarded a qualified contract.

    No more. The US Court of Federal Claims ruled the mandate is unlawful as applied because the “agencies’ own market research conclude[ed] project labor agreements would be anticompetitive,” but the agencies required PLAs anyway. Moving forward, federal agencies must utilize selection criteria designed to award contracts to the most qualified and cost-effective contractor through open competition, regardless of whether that contractor uses union workers.

    Next Steps

    Both developments discussed above reflect the anticipated pro-business policy shifts underway at all federal agencies under the current administration. The US Court of Claims decision applies to the specific contracts at issue in that case and to future agency decisions. It does not apply retroactively. Any contractors currently operating with a PLA must continue to abide by its terms until it expires. Future contracts, however, will not be subject to the PLA requirement.

    Federal contractors bidding on construction contracts or service agreements should quickly reassess current and upcoming contract opportunities and the workforce obligations that come with applying for and maintaining relevant federal contracts. Service contractors will have greater flexibility in managing their workforces and interacting with incumbent unions on predecessor contracts. In addition, potential service contractors without unions can remain union-free while applying for federal contracts.

    Authors

    Tony W. Torain II

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    More insights